+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Gonorrhea Therapeutics Market 2020-2024- Product Image
Global Gonorrhea Therapeutics Market 2020-2024- Product Image

Global Gonorrhea Therapeutics Market 2020-2024

  • ID: 5135918
  • Report
  • July 2020
  • Region: Global
  • 120 pages
  • TechNavio

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Lupin Ltd.
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Gonorrhea Therapeutics Market 2020-2024

The gonorrhea therapeutics market is poised to grow by $ 350.90 mn during 2020-2024 progressing at a CAGR of 5% during the forecast period. The report on the gonorrhea therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of disease, high-risk complications associated with gonorrhea and growing use of new diagnostic tests. In addition, rising prevalence of disease is anticipated to boost the growth of the market as well.

The gonorrhea therapeutics market market analysis includes therapy segment geographic landscapes.

The gonorrhea therapeutics market is segmented as below:

By Therapy
  • Monotherapy
  • Combination therapy
By Geographic Landscapes
  • North America
  • Europe
  • Asia
  • ROW
This study identifies the rising government initiatives to combat antibiotic resistance as one of the prime reasons driving the gonorrhea therapeutics market growth during the next few years. Also, advent of vaccine for prevention of gonorrhea and expedited partner therapy will lead to sizable demand in the market.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The gonorrhea therapeutics market covers the following areas:
  • Gonorrhea therapeutics market sizing
  • Gonorrhea therapeutics market forecast
  • Gonorrhea therapeutics market industry analysis
This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gonorrhea therapeutics market vendors that include AstraZeneca Plc, Bristol-Myers Squibb Co., Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck & Co. Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. Also, the gonorrhea therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.

This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Lupin Ltd.
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Therapy
  • Market segments
  • Comparison by Therapy
  • Monotherapy - Market size and forecast 2019-2024
  • Combination therapy - Market size and forecast 2019-2024
  • Market opportunity by Therapy
Customer landscape
  • Customer landscape
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Overview
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Lupin Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits
1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2019 - 2024 ($ million)
13: Global market: Year-over-year growth 2019 - 2024 (%)
14: Five forces analysis 2019 & 2024
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2019
21: Other1 - Market share 2019-2024 (%)
22: Comparison by Other1
23: Monotherapy - Market size and forecast 2019-2024 ($ million)
24: Monotherapy - Year-over-year growth 2019-2024 (%)
25: Combination therapy - Market size and forecast 2019-2024 ($ million)
26: Combination therapy - Year-over-year growth 2019-2024 (%)
27: Market opportunity by Other1
28: Customer landscape
29: Market share by geography 2019-2024 (%)
30: Geographic comparison
31: North America - Market size and forecast 2019-2024 ($ million)
32: North America - Year-over-year growth 2019-2024 (%)
33: Europe - Market size and forecast 2019-2024 ($ million)
34: Europe - Year-over-year growth 2019-2024 (%)
35: Asia - Market size and forecast 2019-2024 ($ million)
36: Asia - Year-over-year growth 2019-2024 (%)
37: ROW - Market size and forecast 2019-2024 ($ million)
38: ROW - Year-over-year growth 2019-2024 (%)
39: Key leading countries
40: Market opportunity by geography ($ million)
41: Impact of drivers and challenges
42: Vendor landscape
43: Landscape disruption
44: Industry risks
45: Vendors covered
46: Market positioning of vendors
47: AstraZeneca Plc - Overview
48: AstraZeneca Plc - Product and service
49: AstraZeneca Plc - Key offerings
50: AstraZeneca Plc - Key customers
51: AstraZeneca Plc - Segment focus
52: Bristol-Myers Squibb Co. - Overview
53: Bristol-Myers Squibb Co. - Product and service
54: Bristol-Myers Squibb Co. - Key offerings
55: Bristol-Myers Squibb Co. - Key customers
56: Bristol-Myers Squibb Co. - Segment focus
57: Cipla Inc. - Overview
58: Cipla Inc. - Business segments
59: Cipla Inc. - Key offerings
60: Cipla Inc. - Key customers
61: Cipla Inc. - Segment focus
62: F. Hoffmann-La Roche Ltd. - Overview
63: F. Hoffmann-La Roche Ltd. - Business segments
64: F. Hoffmann-La Roche Ltd. - Key offerings
65: F. Hoffmann-La Roche Ltd. - Key customers
66: F. Hoffmann-La Roche Ltd. - Segment focus
67: GlaxoSmithKline Plc - Overview
68: GlaxoSmithKline Plc - Business segments
69: GlaxoSmithKline Plc - Key offerings
70: GlaxoSmithKline Plc - Key customers
71: GlaxoSmithKline Plc - Segment focus
72: Lupin Ltd. - Overview
73: Lupin Ltd. - Product and service
74: Lupin Ltd. - Key offerings
75: Lupin Ltd. - Key customers
76: Lupin Ltd. - Segment focus
77: Merck & Co. Inc. - Overview
78: Merck & Co. Inc. - Business segments
79: Merck & Co. Inc. - Key offerings
80: Merck & Co. Inc. - Key customers
81: Merck & Co. Inc. - Segment focus
82: Pfizer Inc. - Overview
83: Pfizer Inc. - Business segments
84: Pfizer Inc. - Key offerings
85: Pfizer Inc. - Key customers
86: Pfizer Inc. - Segment focus
87: Sun Pharmaceutical Industries Ltd. - Overview
88: Sun Pharmaceutical Industries Ltd. - Business segments
89: Sun Pharmaceutical Industries Ltd. - Key offerings
90: Sun Pharmaceutical Industries Ltd. - Key customers
91: Sun Pharmaceutical Industries Ltd. - Segment focus
92: Teva Pharmaceutical Industries Ltd. - Overview
93: Teva Pharmaceutical Industries Ltd. - Business segments
94: Teva Pharmaceutical Industries Ltd. - Key offerings
95: Teva Pharmaceutical Industries Ltd. - Key customers
96: Teva Pharmaceutical Industries Ltd. - Segment focus
97: Currency conversion rates for US$
98: Research Methodology
99: Validation techniques employed for market sizing
100: Information sources
101: List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Lupin Ltd.
The publisher recognizes the following companies as the key players in the global gonorrhea therapeutics market: AstraZeneca Plc, Bristol-Myers Squibb Co., Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck & Co. Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is rising government initiatives to combat antibiotic resistance."

According to the report, one of the major drivers for this market is the rising prevalence of disease.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Lupin Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll